HRTX vs. SGMO

In the year-to-date period, HRTX achieves a 37.91% return, which is significantly higher than SGMO's -31.35% return. Over the past 10 years, HRTX has outperformed SGMO with an annualized return of -16.05%, while SGMO has yielded a comparatively lower -25.09% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Heron Therapeutics, Inc. (HRTX) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current HRTX Sharpe Ratio is -0.30, which is lower than the SGMO Sharpe Ratio of 0.23. The chart below compares the historical Sharpe Ratios of HRTX and SGMO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither HRTX nor SGMO has paid dividends to shareholders.

The maximum HRTX drawdown since its inception was -99.96%, roughly equal to the maximum SGMO drawdown of -99.40%. Use the drawdown chart below to compare losses from any high point for HRTX and SGMO. For additional features, visit the drawdowns tool.

The current volatility for Heron Therapeutics, Inc. (HRTX) is 23.54%, while Sangamo Therapeutics, Inc. (SGMO) has a volatility of 28.04%. This indicates that HRTX experiences smaller price fluctuations and is considered to be less risky than SGMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Heron Therapeutics, Inc. and Sangamo Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.